#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Robert Hugh BRADBURY et al.	) Confirmation No.: 3653			
Application No.: 10/578,663	) Group Art Unit: Unassigned			
Filed: May 9, 2006	) Examiner: Unassigned			
For: QUINAZOLINE DERIVATIVES	) Date: January 17, 2007			
Commissioner for Patents				
U.S. Patent and Trademark Office				
Customer Window Mail Ston Amendment				

Sir:

Randolph Building 401 Dulany Street Alexandria, VA 22314

# SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

#### UNDER 37 C.F.R. § 1.97(b)

## Citation of Technically Related U.S. Patent Applications

The Examiner's attention is directed to the following technically related U.S. patents or applications of Applicants' assignee:

Inventor	U.S. Serial No.	U.S. Patent No.	PCT Publication No.	
	Filing Date .	Issue Date	PCT Publication Date	
Hennequin et al.	11/443,395		WO 03/040109	
· ·	May 31, 2006		May 15, 2003	
Hennequin et al.	11/443,208		WO 03/040108	
	May 31, 2006		May 15, 2003	
Bradbury et al.	10/554,202		WO 2004/093880	
	October 24, 2005		November 4, 2004	
Bradbury et al.	10/571,851		WO 2005/026151	
	March 15, 2006		March 24, 2005	
Bradbury et al.	10/572,262		WO 2005/026152	
	March 16, 2006		March 24, 2005	
Bradbury et al.	10/857,342		WO 2005/012290	
	June 1, 2004		November 4, 2004	
Bradbury et al.	11/628,011		WO 2005/118572	
	November 30, 2006		December 15, 2005	

Page 2

With the exception of the documents listed in the table above in bold (for which a copy was

provided with the previously filed Information Disclosure Statement), a copy of the specification and

claims for each application, in the form of the published PCT application from which such application

was filed is being filed herewith. Consideration of each listed application is earnestly solicited

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants request the Examiner to consider this

Supplemental Information Disclosure Statement and the documents listed on the attached Form PTO-

1449. To the best of the undersigned's knowledge, this Supplemental Information Disclosure Statement

is being filed before the mailing date of a first Office Action on the merits for the above-referenced

application. Accordingly, Applicants do not believe a fee is due for filing this Supplemental Information

Disclosure Statement

Copies of the listed documents are attached. Applicants respectfully request that the Examiner

initial and return the Form PTO-1449, indicating that the information has been considered and made of

record herein.

This submission does not represent that a search has been made or that no better art exists and

does not constitute an admission that each or all of the listed documents are material or constitute "prior

art." Applicants reserve the right to take appropriate action to establish the patentability of the disclosed

invention over the listed documents, should one or more of the documents be applied against the claims of

the present application.

Except for issue fees payable under 37 C.F.R. §1.18, the Commissioner is hereby authorized by

this paper to charge any additional fees during the entire pendency of this application including fees due

under 37 C.F.R. §§1.16 and 1.17 which may be required, including any required extension of time fees, or

credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a

1-WA/2686688.1

### CONSTRUCTIVE PETITION FOR EXTENSION OF TIME in accordance with 37 C.F.R.

§1.136(a)(3).

Date: January 17, 2007 Morgan Lewis & Bockius LLP Customer No. 09629 1111 Pennsylvania Avenue, N.W. Washington, D.C. 20004 Tel. No.: 202-739-3000 By:

Donald J. Bird Registration No. 25,323 Tel. No.: (202) 739-5320 Fax No.: (202) 739-3001

Respectfully Submitted, Morgan Lewis & Bockius

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)  PTO Form 1449 January 17, 2007		N	Attorney Docket No. 056291-5283			Application No. 10/578,663			
		A	Applicants: Robert Hugh BRADBURY et al.						
			Filing Date: May 9, 2006			Group Art Unit: Unassigned			
		II S	PATE	NT DOCU	MENTS				
Initial		Document No. Date		Name		Cla	s Sub-Class	Filing Date	
			-						
						1			
		FOREIG	GN PA	TENT DO	CUMENTS				
		Document No. Date		C	ountry	Clas	s Sub-Class	Translation	
	1.	WO 2005/012290 November 4, 2			VIPO				
_	2.	WO 2005/118572 December 15,			VIPO				
	3.	WO 2006/008526 January 26, 2	006		VIPO				
A	LL RE	<del>FERENCES CONSIDERED EXCE</del>	PT-W	HERE LIN	ED THROU	<del>иdн. /т</del>	.N.\	L	
		OTHER DOCUMENTS (Inc	dudina	Author T	itle Date Pe	ertinent l	Pages etc.)		
	S.							tency and in vivo	
	-	Ballard et al. "Inhibitors of epidermal growth factor receptor tyrosine kinase: optimisation of potency and in vivo pharmacokinetics" Bioorg Med Chem Lett. 16(18):4908-4912 (2006).							
	5.	Harris et al. "Facile synthesis of 7-amino anilinoquinazolines via direct amination of the quinazoline core" Tetrahed letters 46(43):7381-7384 (2005).							
	6.	Harris et al. "Selective alkylation of a 6,							
	7.	Hennequin et al. "Novel 4-anilinoquinazolines with C-6 carbon-linked side chains: synthesis and structure-activity relationship of a series of potent, orally active, EGF receptor tyrosine kinase inhibitors" Bioorg Med Chem Lett. 16(10):2672-2676 (2006) -							
	8.								
	9.	Traxler et al. "Protein tyrosine kinase inhibitors in cancer treatment" Exp. Opin. Ther. Patents 7(6):571-588 (1997) -							
	10.	Traxler et al. "Tyrosine kinase inhibitors (1998) .							
	<ol> <li>Tsou et al. "6-Substituted-4(3-bromophenylamino)quinazolines as Putative Irreversible Inhibitors of the E Growth Factor Receptor (EGFR) and Human Epidermal Growth Factor Receptor (HER-2) Tyrosine Kinast Enhanced Antitumer Activity" J. Med. Chem. 44:2119-2734 (2001).</li> </ol>								
	<ol> <li>Vema et al. "Design of EGFR kinase inhibitors: a ligand-based approach and its confirmation with stru studies" Bioorg Med Chem. 11(21):4643-4653 (2003)</li> </ol>							vith structure-based	
		ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /T.N./							
	-							W-W	
	$\vdash$								
								-	
	L_								
xaminer		/Tamthom Truong/	te Cons	sidered	09/05/20	08			
	. Inde	al if reference considered, whether or not	-14-41	:-: r			O. dames 15 4		

1-WA/2686687.1 Page 1 of 1